Past research interests include the use of biomarkers (from blood, urine, and breath) to screen for and monitor cancer as well as chemotherapy toxicity (specifically cardiotoxicity), novel anticancer chemotherapy drugs, samarium-153-DOTMP (a bone-seeking radiopharmaceutical) to treat primary and metastatic bone cancer, and improved estimation of body surface area for more accurate dosing of anticancer drugs.
Current research interests include continued research on cardiotoxicity, novel anticancer drugs, improved multimodal treatment of feline oral squamous cell carcinoma, and an overarching goal to develop an improved understanding of the effect of radiation and various fractionation schedules on the tumor microenvironment.
Dr. Selting has focused more of her work on solid tumors such as osteosarcoma.
